News and Announcements
Phylogica and Bio-Link Collaborate to Commercialise Anti-Inflammatory Phylomers
- Published February 05, 2013 9:14AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
PERTH, AUSTRALIA: February 05, 2013 – Phylogica Ltd (ASX: PYC, XETRA: PH7), a leading Australian peptide drug discovery company, announced today that it has entered an agreement with Bio-Link Australia Pty. Ltd., a specialist life sciences business development company, to commercialise a family of anti-inflammatory PhylomerÒ peptides for pharmaceutical use. Under the terms of the agreement, Bio-Link will work with Phylogica to monetize these assets through out-licensing or disposal of the Phylomer peptides to a pharmaceutical or biotechnology company.
To read full announcement, please download the document below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
